RXRX Stock jumps after JPMorgan upgrade and trial data boost, fueling investor optimism in Recursion’s AI drug discovery ...

Wondering if Recursion Pharmaceuticals at around $4.83 is a beaten down bargain or a value trap? This breakdown walks through what the current market price is really implying. The stock has bounced ...

The simulation hypothesis—the idea that our universe might be an artificial construct running on some advanced alien computer ...

In early December 2025, Recursion Pharmaceuticals released clinical data from the TUPELO Phase 1b/2 trial of REC-4881, providing fresh insight into the candidate’s safety and efficacy profile. This ...

Recursion Pharmaceuticals (RXRX) stock rises after J.P. Morgan upgraded the biotech, citing a $1B+ sales potential for the company's lead drug. Read more here.

Earlier in December 2025, Recursion Pharmaceuticals reported positive Phase 1b/2 TUPELO trial data for REC-4881 in familial adenomatous polyposis, showing rapid and durable reductions in polyp burden ...

Shares of Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) are trading higher Monday after the pharmaceutical company reported positive data from an ongoing trial. What To Know: Recursion ...

The native just-in-time compiler in Python 3.15 can speed up code by as much as 20% or more, although it’s still experimental ...

In 2025, Anthropic will grow from $1 billion to $9 billion in ARR (annual recurring revenue). OpenAI, meanwhile, will go from ...

A new research paper reframes the simulation hypothesis, asking whether reality could be simulated and what science can test.